Patent information
IP India · live recordAbstract
ABSTRACT A PROCESS FOR THE PREPARATION OF FORM III OF CORTEXOLONE 17a-PROPIONATE Disclosed herein is a process for the preparation of crystalline form III of cortexolone 17a-propionate of formula (I) Formula (I) which comprises providing a solution of cortexolone 17a-propionate in ethanol; combining the solution of cortexolone 17a-propionate with n-hexane to obtain a mixture; maintaining the mixture at a temperature between 0 oC and 5 oC and stirring the mixture for a time between 25 and 35 minutes; and isolating crystalline Form III of cortexolone 17a-propionate.
Applicants
1Inventors
4Specification
Show full textCollapse
1. A process for the preparation of crystalline Form III of Cortexolone 17α-propionate of formula (I) 2. The process as claimed in Claim 1, wherein the amount of ethanol used for providing a solution of cortexolone 17α-propionate in ethanol in step a) is about 3 ml per gram of cortexolone 17α-propionate. 3. The process as claimed in Claim 1, wherein ethanol and n-hexane are used in the 25 ratio of about 1:2. 4. The process as claimed in Claim 1, wherein the water content of the mixture is less than about 10%. 5. The process as claimed in Claim 1, wherein the mixture obtained in step b) is cooled to a temperature of about 0 oC (± 2 oC), maintained at a temperature of 0 oC (± 2 oC) and stirred for 30 minutes at 0 oC (± 2 o 10 C). 6. The process as claimed in Claim 1, wherein the crystalline Form III of cortexolone 17α-propionate is isolated by filtration and is further washed with n-hexane. 15 7. The process as claimed in Claim 6, wherein the isolated crystalline Form III of cortexolone 17α-propionate is dried at temperatures from about 40°C to about 50°C, under a vacuum for a time between about 7 hours and about 9 hours. 8. The process as claimed in Claim 1, wherein the crystalline Form III of Cortexolone 20 17α-propionate is stable and has a purity of greater than 99.0%, wherein stable means that after 2 months at 25±2°C and 60±5% relative humidity or at 2-8°C all impurities are below 1.0%. 9. The process as claimed in Claim 1, wherein the crystalline Form III of cortexolone 25 17α-propionate is characterized by a powder x-ray diffraction pattern as substantially depicted in FIG. 1. 10. The process as claimed in Claim 1, wherein the crystalline Form III of cortexolone 17α-propionate is characterized by a powder x-ray diffraction pattern having peaks 30 at about 6.35, 12.71, 14.18, 14.4, 16.1, 22.5, and 23.8 degrees 2 theta (±0.2°).